Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Recent Advances in Precision Image-Guided Cancer Therapy
share announcement

Recent Advances in Precision Image-Guided Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (1 March 2023) | Viewed by 10584

Special Issue Editors

Dr. J. Sven D. Mieog

E-Mail Website
Guest Editor
Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
Interests: HPB oncology; fluorescence-guided surgery; molecular-targeted medicine
Prof. Dr. Schelto Kruijff

E-Mail Website
Guest Editor
Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Interests: endocrine surgery; fluorescence-guided surgery; opto-acoustic imaging

Special Issue Information

Dear Colleagues, 

This Special Issue will cover the latest developments in the field of image-guided surgery incorporating different imaging modalities. The discussion of novel methods, imaging systems, imaging agents, and new applications is encouraged. Both preclinical and clinical studies are eligible, as well as reviews covering overviews of the field of image-guided surgery and future prospects.

The aim of this Special Issue is to provide a concise overview of the current standing of the field of image-guided surgery, to offer a platform to demonstrate the latest developments, and to discuss future steps to move the field forward.

Current status of image-guided surgery:

1. Fluorescence-guided

  1.  Endogenous contrast (hyperspectral, etc)
  2.  Exogenous contrast
    1. 1st-generation imaging agents (indocyanine green, methylene blue)
    2. 2nd-generation imaging agents (targeting whole antibodies, new dyes)
    3. 3rd-generation imaging agents (targeting small molecules)

2.  Photo-acoustic, optoacoustic imaging

3.  Intra-operative ultrasound

4.  Combination with radio-guidance and image-guided

5.  Image-guided thermal ablative therapies

6.  Image-guided phototherapy

7.  Other forms of image-guided local cancer therapies

Dr. J. Sven D. Mieog
Prof. Dr. Schelto Kruijff
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • image-guided surgery
  • fluorescence
  • intraoperative ultrasound
  • photo/opto-acoustic imaging
  • radio-guidance
  • cancer surgery
  • imaging of tissue perfusion

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

23 pages, 16038 KiB  
Article
Mapping Resection Progress by Tool-Tip Tracking during Brain Tumor Surgery for Real-Time Estimation of Residual Tumor
by Parikshit Juvekar, Erickson Torio, Wenya Linda Bi, Dhiego Chaves De Almeida Bastos, Alexandra J. Golby and Sarah F. Frisken
Cancers 2023, 15(3), 825; https://doi.org/10.3390/cancers15030825 - 29 Jan 2023
Cited by 2 | Viewed by 2011
Abstract
Surgical resection continues to be the primary initial therapeutic strategy in the treatment of patients with brain tumors. Computerized cranial neuronavigation based on preoperative imaging offers precision guidance during craniotomy and early tumor resection but progressively loses validity with brain shift. Intraoperative MRI [...] Read more.
Surgical resection continues to be the primary initial therapeutic strategy in the treatment of patients with brain tumors. Computerized cranial neuronavigation based on preoperative imaging offers precision guidance during craniotomy and early tumor resection but progressively loses validity with brain shift. Intraoperative MRI (iMRI) and intraoperative ultrasound (iUS) can update the imaging used for guidance and navigation but are limited in terms of temporal and spatial resolution, respectively. We present a system that uses time-stamped tool-tip positions of surgical instruments to generate a map of resection progress with high spatial and temporal accuracy. We evaluate this system and present results from 80 cranial tumor resections. Regions of the preoperative tumor segmentation that are covered by the resection map (True Positive Tracking) and regions of the preoperative tumor segmentation not covered by the resection map (True Negative Tracking) are determined for each case. We compare True Negative Tracking, which estimates the residual tumor, with the actual residual tumor identified using iMRI. We discuss factors that can cause False Positive Tracking and False Negative Tracking, which underestimate and overestimate the residual tumor, respectively. Our method provides good estimates of the residual tumor when there is minimal brain shift, and line-of-sight is maintained. When these conditions are not met, surgeons report that it is still useful for identifying regions of potential residual. Full article
(This article belongs to the Special Issue Recent Advances in Precision Image-Guided Cancer Therapy)
►▼ Show Figures

Figure 1

14 pages, 276 KiB  
Article
Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons’ Perspectives on Current Use and Future Recommendations
by Lysanne D. A. N. de Muynck, Kevin P. White, Adnan Alseidi, Elisa Bannone, Luigi Boni, Michael Bouvet, Massimo Falconi, Hans F. Fuchs, Michael Ghadimi, Ines Gockel, Thilo Hackert, Takeaki Ishizawa, Chang Moo Kang, Norihiro Kokudo, Felix Nickel, Stefano Partelli, Elena Rangelova, Rutger Jan Swijnenburg, Fernando Dip, Raul J. Rosenthal, Alexander L. Vahrmeijer and J. Sven D. Mieogadd Show full author list remove Hide full author list
Cancers 2023, 15(3), 652; https://doi.org/10.3390/cancers15030652 - 20 Jan 2023
Cited by 4 | Viewed by 2143
Abstract
Indocyanine green (ICG) is one of the only clinically approved near-infrared (NIR) fluorophores used during fluorescence-guided surgery (FGS), but it lacks tumor specificity for pancreatic ductal adenocarcinoma (PDAC). Several tumor-targeted fluorescent probes have been evaluated in PDAC patients, yet no uniformity or consensus [...] Read more.
Indocyanine green (ICG) is one of the only clinically approved near-infrared (NIR) fluorophores used during fluorescence-guided surgery (FGS), but it lacks tumor specificity for pancreatic ductal adenocarcinoma (PDAC). Several tumor-targeted fluorescent probes have been evaluated in PDAC patients, yet no uniformity or consensus exists among the surgical community on the current and future needs of FGS during PDAC surgery. In this first-published consensus report on FGS for PDAC, expert opinions were gathered on current use and future recommendations from surgeons’ perspectives. A Delphi survey was conducted among international FGS experts via Google Forms. Experts were asked to anonymously vote on 76 statements, with ≥70% agreement considered consensus and ≥80% participation/statement considered vote robustness. Consensus was reached for 61/76 statements. All statements were considered robust. All experts agreed that FGS is safe with few drawbacks during PDAC surgery, but that it should not yet be implemented routinely for tumor identification due to a lack of PDAC-specific NIR tracers and insufficient evidence proving FGS’s benefit over standard methods. However, aside from tumor imaging, surgeons suggest they would benefit from visualizing vasculature and surrounding anatomy with ICG during PDAC surgery. Future research could also benefit from identifying neuroendocrine tumors. More research focusing on standardization and combining tumor identification and vital-structure imaging would greatly improve FGS’s use during PDAC surgery. Full article
(This article belongs to the Special Issue Recent Advances in Precision Image-Guided Cancer Therapy)
12 pages, 20650 KiB  
Article
Deploying Indocyanine Green Fluorescence-Guided Navigation System in Precise Laparoscopic Resection of Pediatric Hepatoblastoma
by Ronglin Qiu, Yaohao Wu, Jianhang Su, Luping Chen, Minyi Liao, Zhuangjie Zhao, Zijie Lu, Xiangang Xiong, Shikai Jin and Xiaogeng Deng
Cancers 2022, 14(24), 6057; https://doi.org/10.3390/cancers14246057 - 9 Dec 2022
Cited by 4 | Viewed by 1379
Abstract
Background: Hepatoblastoma (HB) is the most common form of liver cancer in children. To date, complete tumor resection is still the gold standard for treating HB. Indocyanine green (ICG) has been identified as a sensitive adjunct that is highly effective in the [...] Read more.
Background: Hepatoblastoma (HB) is the most common form of liver cancer in children. To date, complete tumor resection is still the gold standard for treating HB. Indocyanine green (ICG) has been identified as a sensitive adjunct that is highly effective in the identification and surgical management of local and metastatic HB. It has thus becomes an increasingly popular choice among surgeons in HB resection surgeries that are fluorescence-guided. However, laparotomy remains the preferred choice in most cases since the applications and limitations of fluorescence-guided laparoscopic surgery in treating HB remain unclear. In this study, the characteristics and outcomes of laparoscopic HB resections that were guided by intraoperative ICG fluorescent imaging were investigated. Methods: Seven HB patients underwent ICG-guided laparoscopic HB resection surgery from August 2019 to December 2021. ICG was intravenously administered to the patients at a dosage of 0.5 mg/kg 48 h prior to the scheduled operation. During operation, tumor localization and resection boundary were guided by fluorescence visualization. The data on surgical and clinical features were collected retrospectively. Results: The resection area and tumor boundary could be clearly viewed in real-time under the ICG fluorescence imaging navigation system during operation, except for one patient who had received interventional chemoembolization before surgery. The image produced by laparoscopic fluorescence navigation was clear since it was not affected by ambient light. All tumors were completely resected as confirmed by negative margins for HB during postoperative pathological examination. No residual or recurrence were also found through computed tomography during follow-up visits from 9 to 37 months. Conclusions: ICG fluorescence-guided laparoscopic surgery is safe and effective in treating HB due to its ability to provide clear information on tumor localization and delineate tumor margins in real-time. Full article
(This article belongs to the Special Issue Recent Advances in Precision Image-Guided Cancer Therapy)
►▼ Show Figures

Figure 1

20 pages, 6508 KiB  
Article
Delta-Radiomics Based on Dynamic Contrast-Enhanced MRI Predicts Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
by Liangcun Guo, Siyao Du, Si Gao, Ruimeng Zhao, Guoliang Huang, Feng Jin, Yuee Teng and Lina Zhang
Cancers 2022, 14(14), 3515; https://doi.org/10.3390/cancers14143515 - 20 Jul 2022
Cited by 15 | Viewed by 2762
Abstract
Objective: To investigate the value of delta-radiomics after the first cycle of neoadjuvant chemotherapy (NAC) using dynamic contrast-enhanced (DCE) MRI for early prediction of pathological complete response (pCR) in patients with breast cancer. Methods: From September 2018 to May 2021, a total of [...] Read more.
Objective: To investigate the value of delta-radiomics after the first cycle of neoadjuvant chemotherapy (NAC) using dynamic contrast-enhanced (DCE) MRI for early prediction of pathological complete response (pCR) in patients with breast cancer. Methods: From September 2018 to May 2021, a total of 140 consecutive patients (training, n = 98: validation, n = 42), newly diagnosed with breast cancer who received NAC before surgery, were prospectively enrolled. All patients underwent DCE-MRI at pre-NAC (pre-) and after the first cycle (1st-) of NAC. Radiomic features were extracted from the postcontrast early, peak, and delay phases. Delta-radiomics features were computed in each contrast phases. Least absolute shrinkage and selection operator (LASSO) and a logistic regression model were used to select features and build models. The model performance was assessed by receiver operating characteristic (ROC) analysis and compared by DeLong test. Results: The delta-radiomics model based on the early phases of DCE-MRI showed a highest AUC (0.917/0.842 for training/validation cohort) compared with that using the peak and delay phases images. The delta-radiomics model outperformed the pre-radiomics model (AUC = 0.759/0.617, p = 0.011/0.047 for training/validation cohort) in early phase. Based on the optimal model, longitudinal fusion radiomic models achieved an AUC of 0.871/0.869 in training/validation cohort. Clinical-radiomics model generated good calibration and discrimination capacity with AUC 0.934 (95%CI: 0.882, 0.986)/0.864 (95%CI: 0.746, 0.982) for training and validation cohort. Delta-radiomics based on early contrast phases of DCE-MRI combined clinicopathology information could predict pCR after one cycle of NAC in patients with breast cancer. Full article
(This article belongs to the Special Issue Recent Advances in Precision Image-Guided Cancer Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 890 KiB  
Review
A Narrative Review of the Usefulness of Indocyanine Green Fluorescence Angiography for Perfusion Assessment in Colorectal Surgery
by Masayoshi Iwamoto, Kazuki Ueda and Junichiro Kawamura
Cancers 2022, 14(22), 5623; https://doi.org/10.3390/cancers14225623 - 16 Nov 2022
Cited by 6 | Viewed by 1762
Abstract
Anastomotic leakage is one of the most dreaded complications of colorectal surgery and is strongly associated with tissue perfusion. Indocyanine green fluorescence angiography (ICG-FA) using indocyanine green and near-infrared systems is an innovative technique that allows the visualization of anastomotic perfusion. Based on [...] Read more.
Anastomotic leakage is one of the most dreaded complications of colorectal surgery and is strongly associated with tissue perfusion. Indocyanine green fluorescence angiography (ICG-FA) using indocyanine green and near-infrared systems is an innovative technique that allows the visualization of anastomotic perfusion. Based on this information on tissue perfusion status, surgeons will be able to clearly identify colorectal segments with good blood flow for safer colorectal anastomosis. The results of several clinical trials indicate that ICG-FA may reduce the risk of AL in colorectal resection; however, the level of evidence is not high, as several other studies have failed to demonstrate a reduction in the risk of AL. Several large-scale RCTs are currently underway, and their results will determine whether ICG-FA is, indeed, useful. The major limitation of the current ICG-FA evaluation method, however, is that it is subjective and based on visual assessment by the surgeon. To complement this, the utility of objective evaluation methods for fluorescence using quantitative parameters is being investigated. Promising results have been reported from several clinical trials, but all trials are preliminary owing to their small sample size and lack of standardized protocols for quantitative evaluation. Therefore, appropriately standardized, high-quality, large-scale studies are warranted. Full article
(This article belongs to the Special Issue Recent Advances in Precision Image-Guided Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop